脂質異常症患者を対象としたAZD8233の研究。

基本情報

NCT ID: NCT04823611
ステータス: 完了
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 87
治験依頼者名: AstraZeneca

概要

A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of Part A , Part B and Part C. Part A is designed as a randomized, single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study. Part C is designed as a randomized , single-blind (blinding of participants and sites), placebo-controlled, multiple dose, phase 1 study.

対象疾患

Dyslipidemia

介入

Part A:Placebo(DRUG)

Part A:AZD8233(DRUG)

Part B:Placebo(DRUG)

Part B:AZD8233(DRUG)

Part C: Placebo(DRUG)

Part C: AZD8233(DRUG)

依頼者（Sponsor）

アストラゼネカ株式会社(INDUSTRY)